^
Association details:
| Biomarker: | ER D538G + ER F404L |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | fulvestrant (Selective estrogen receptor degrader) |
| Direction: | Resistant |
Evidence:
Source:
Title:
ESR1 F404 mutations and acquired resistance to fulvestrant in the plasmaMATCH study
Published date:
05/26/2022
Excerpt:
Transient transfection demonstrated that single mutations D538G, E380Q, F404L and wild-type ESR1 were sensitive to fulvestrant (p < 0.0001, p = 0.0006, p = 0.04 and p = 0.0001), whereas compound mutations D538G_F404L and E380Q_F404L were resistant.
DOI:
10.1200/JCO.2022.40.16_suppl.1009
Trial ID:
Test:
